OmniAb, Inc.
OABI Healthcare Biotechnology
OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024.
- Revenue
- +78.3%
- EPS
- +14.3%
- Free cash flow
- +206.3%
Quarter to September 2026, against a year earlier
Follow OABI
Alert me
OmniAb, Inc. (OABI) EV/Sales
As of 6 November 2026, OmniAb, Inc. (OABI) trades at a EV/Sales of 14.5×. Over the past ten years it has ranged from 0.0× (December 2022) to 22.7× (April 2024); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.4× | (27.10%) |
| FY2024 | 11.5× | (26.84%) |
| FY2023 | 15.7× | 346.10% |
| FY2022 | 3.5× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 14.4× | 108.40% |
| Jun 2026 | 6.9× | 30.88% |
| Mar 2026 | 5.3× | (37.12%) |
| Dec 2025 | 8.4× | 42.28% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SANA Sana Biotechnology, Inc. compare | n/m |
| ATTO Attovia Therapeutics, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| ARDX Ardelyx, Inc. compare | 1.5× |
| DNA Ginkgo Bioworks Holdings, Inc. compare | 4.0× |
| OABI OmniAb, Inc. | 14.5× |
| LXRX Lexicon Pharmaceuticals, Inc. compare | 17.4× |
| SLDB Solid Biosciences Inc. compare | 57.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)